Santarus Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Salix Pharma
08 Novembre 2013 - 5:32PM
Business Wire
Former United States Securities and Exchange Commission attorney
Willie Briscoe and the securities litigation firm of Powers Taylor
LLP are investigating potential claims against the Board of
Directors of Santarus, Inc. (“Santarus”) (NasdaqGS: SNTS) related
to the acquisition by Salix Pharma for shareholders. Under the
terms of the proposed transaction, Santarus shareholders will only
receive $32.00 in cash for each share of Santarus stock owned.
If you are an affected investor, and you want to learn more
about the lawsuit or join the action, contact Willie Briscoe at The
Briscoe Law Firm, PLLC, (214) 239-4568, or via email at
WBriscoe@TheBriscoeLawFirm.com, or Zach Groover at Powers Taylor
LLP, toll free (877) 728-9607, via e-mail at
shareholder@powerstaylor.com. There is no cost or fee to you.
The Santarus investigation centers on whether Santarus’ Board of
Directors is acting in the shareholders’ best interests, whether
the board is properly considering the proposed price for the
shareholders, and whether the board has employed an adequate
process to review and act on the proposed transaction.
The Briscoe Law Firm, PLLC is a full service business litigation
and shareholder rights advocacy firm with more than 20 years of
experience in complex litigation and transactional matters.
Powers Taylor LLP is a boutique litigation law firm that handles
a variety of complex business litigation matters, including claims
of investor and stockholder fraud, shareholder oppression,
shareholder derivative suits, and security class actions.
The Briscoe Law Firm, PLLCWillie Briscoe,
214-239-4568WBriscoe@TheBriscoeLawFirm.comorPowers Taylor LLPZach
Groover, 877-728-9607shareholder@powerstaylor.com
Santarus (NASDAQ:SNTS)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Santarus (NASDAQ:SNTS)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Santarus, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Santarus, Inc. (MM)